Applying a common data model to asian databases for multinational pharmacoepidemiologic studies: Opportunities and challenges

Edward Chia Cheng Lai, Patrick Ryan, Yinghong Zhang, Martijn Schuemie, N. Chantelle Hardy, Yukari Kamijima, Shinya Kimura, Kiyoshi Kubota, Kenneth K.C. Man, Soo Yeon Cho, Rae Woong Park, Paul Stang, Chien Chou Su, Ian C.K. Wong, Yea Huei Yang Kao, Soko Setoguchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort. Study design and setting: We converted data from the Japan Medical Data Center database, Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis and Reporting System, South Korea’s Ajou University School of Medicine database, and the US Medicare 5% sample to the Observational Medical Outcome Partnership common data model (CDM). Results: We completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90% of diagnosis and procedure codes to standard terminology codes. Conclusion: The CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.

Original languageEnglish (US)
Pages (from-to)875-885
Number of pages11
JournalClinical Epidemiology
Volume10
DOIs
StatePublished - Jan 1 2018

Fingerprint

RxNorm
Databases
Terminology
Pharmacoepidemiology
Pharmaceutical Preparations
National Health Programs
Hong Kong
Korea
Medicare
Taiwan
Japan
Research Design
Medicine
Safety
Health
Research
Therapeutics

All Science Journal Classification (ASJC) codes

  • Epidemiology

Keywords

  • Clinical coding
  • Computer communication networks
  • Feasibility studies
  • Pharmacoepidemiology
  • Pharmacovigilance

Cite this

Lai, Edward Chia Cheng ; Ryan, Patrick ; Zhang, Yinghong ; Schuemie, Martijn ; Hardy, N. Chantelle ; Kamijima, Yukari ; Kimura, Shinya ; Kubota, Kiyoshi ; Man, Kenneth K.C. ; Cho, Soo Yeon ; Park, Rae Woong ; Stang, Paul ; Su, Chien Chou ; Wong, Ian C.K. ; Kao, Yea Huei Yang ; Setoguchi, Soko. / Applying a common data model to asian databases for multinational pharmacoepidemiologic studies : Opportunities and challenges. In: Clinical Epidemiology. 2018 ; Vol. 10. pp. 875-885.
@article{992115272cde417585d73473e80c2ef1,
title = "Applying a common data model to asian databases for multinational pharmacoepidemiologic studies: Opportunities and challenges",
abstract = "Objective: The goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort. Study design and setting: We converted data from the Japan Medical Data Center database, Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis and Reporting System, South Korea’s Ajou University School of Medicine database, and the US Medicare 5{\%} sample to the Observational Medical Outcome Partnership common data model (CDM). Results: We completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2{\%}, 86.7{\%}, 92.6{\%}, and 80.1{\%} of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7{\%}) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90{\%} of diagnosis and procedure codes to standard terminology codes. Conclusion: The CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.",
keywords = "Clinical coding, Computer communication networks, Feasibility studies, Pharmacoepidemiology, Pharmacovigilance",
author = "Lai, {Edward Chia Cheng} and Patrick Ryan and Yinghong Zhang and Martijn Schuemie and Hardy, {N. Chantelle} and Yukari Kamijima and Shinya Kimura and Kiyoshi Kubota and Man, {Kenneth K.C.} and Cho, {Soo Yeon} and Park, {Rae Woong} and Paul Stang and Su, {Chien Chou} and Wong, {Ian C.K.} and Kao, {Yea Huei Yang} and Soko Setoguchi",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/CLEP.S149961",
language = "English (US)",
volume = "10",
pages = "875--885",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd.",

}

Lai, ECC, Ryan, P, Zhang, Y, Schuemie, M, Hardy, NC, Kamijima, Y, Kimura, S, Kubota, K, Man, KKC, Cho, SY, Park, RW, Stang, P, Su, CC, Wong, ICK, Kao, YHY & Setoguchi, S 2018, 'Applying a common data model to asian databases for multinational pharmacoepidemiologic studies: Opportunities and challenges', Clinical Epidemiology, vol. 10, pp. 875-885. https://doi.org/10.2147/CLEP.S149961

Applying a common data model to asian databases for multinational pharmacoepidemiologic studies : Opportunities and challenges. / Lai, Edward Chia Cheng; Ryan, Patrick; Zhang, Yinghong; Schuemie, Martijn; Hardy, N. Chantelle; Kamijima, Yukari; Kimura, Shinya; Kubota, Kiyoshi; Man, Kenneth K.C.; Cho, Soo Yeon; Park, Rae Woong; Stang, Paul; Su, Chien Chou; Wong, Ian C.K.; Kao, Yea Huei Yang; Setoguchi, Soko.

In: Clinical Epidemiology, Vol. 10, 01.01.2018, p. 875-885.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Applying a common data model to asian databases for multinational pharmacoepidemiologic studies

T2 - Opportunities and challenges

AU - Lai, Edward Chia Cheng

AU - Ryan, Patrick

AU - Zhang, Yinghong

AU - Schuemie, Martijn

AU - Hardy, N. Chantelle

AU - Kamijima, Yukari

AU - Kimura, Shinya

AU - Kubota, Kiyoshi

AU - Man, Kenneth K.C.

AU - Cho, Soo Yeon

AU - Park, Rae Woong

AU - Stang, Paul

AU - Su, Chien Chou

AU - Wong, Ian C.K.

AU - Kao, Yea Huei Yang

AU - Setoguchi, Soko

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: The goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort. Study design and setting: We converted data from the Japan Medical Data Center database, Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis and Reporting System, South Korea’s Ajou University School of Medicine database, and the US Medicare 5% sample to the Observational Medical Outcome Partnership common data model (CDM). Results: We completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90% of diagnosis and procedure codes to standard terminology codes. Conclusion: The CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.

AB - Objective: The goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort. Study design and setting: We converted data from the Japan Medical Data Center database, Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis and Reporting System, South Korea’s Ajou University School of Medicine database, and the US Medicare 5% sample to the Observational Medical Outcome Partnership common data model (CDM). Results: We completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90% of diagnosis and procedure codes to standard terminology codes. Conclusion: The CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.

KW - Clinical coding

KW - Computer communication networks

KW - Feasibility studies

KW - Pharmacoepidemiology

KW - Pharmacovigilance

UR - http://www.scopus.com/inward/record.url?scp=85057741696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057741696&partnerID=8YFLogxK

U2 - 10.2147/CLEP.S149961

DO - 10.2147/CLEP.S149961

M3 - Article

AN - SCOPUS:85057741696

VL - 10

SP - 875

EP - 885

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -